FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB	APP	RO\	/AI

OMB Number:	3235-0287
Estimated average burde	en
hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

affirmative defens 10b5-1(c). See In	se conditions of Rule struction 10.			
1. Name and Address	. 0	son*	2. Issuer Name and Ticker or Trading Symbol Emmaus Life Sciences, Inc. [EMMA]	S. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 02/26/2024	X Officer (give title Other (specify below)
21250 HAWTH	ORNE BLVD.			Co-President & COO
SUITE 800			4. If Amendment, Date of Original Filed (Month/Day/Year)	Individual or Joint/Group Filing (Check Applicable Line X Form filed by One Reporting Person
(Street)				Form filed by More than One Reporting Perso
TORRANCE	CA	90503		Form filed by More than One Reporting Perso
(City)	(State)	(Zip)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount (A) (D)		Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common stock, \$0.001 par value	02/26/2024		P		13,200	A	\$0.12(1)	57,400	I	By Fidelity Roth IRA FBO Willis C. Lee	
Common stock, \$0.001 par value	02/27/2024		P		10,000	A	\$0.13	67,400	I	By Fidelity Roth IRA FBO Willis C. Lee	
Common stock, \$0.001 par value	02/28/2024		P		15,000	A	\$ 0.12 ⁽²⁾	82,400	I	By Fidelity Roth IRA FBO Willis C. Lee	
Common stock, \$0.001 par value	02/29/2024		P		77,000	A	\$0.13	159,400	I	By Fidelity Roth IRA FBO Willis C. Lee	
Common stock, \$0.001 par value								395,124	D		
Common stock, \$0.001 par value								241,194	I	By Fidelity Traditional IRA FBO Willis C. Lee	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

											<u> </u>				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)		Derivative		Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	(I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		

Explanation of Responses:

- 1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$0.12 to \$0.13, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (2) to this Form 4.
- 2. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$0.12 to \$0.13, inclusive.

Remarks:

Willis C. Lee 02/29/2024

** Signature of Reporting Person

Data

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.